Back to Search Start Over

Performance of crisis standards of care guidelines in a cohort of critically ill COVID-19 patients in the United States.

Authors :
Jezmir JL
Bharadwaj M
Chaitoff A
Diephuis B
Crowley CP
Kishore SP
Goralnick E
Merriam LT
Milliken A
Rhee C
Sadovnikoff N
Shah SB
Gupta S
Leaf DE
Feldman WB
Kim EY
Source :
Cell reports. Medicine [Cell Rep Med] 2021 Sep 21; Vol. 2 (9), pp. 100376. Date of Electronic Publication: 2021 Jul 28.
Publication Year :
2021

Abstract

Many US states published crisis standards of care (CSC) guidelines for allocating scarce critical care resources during the COVID-19 pandemic. However, the performance of these guidelines in maximizing their population benefit has not been well tested. In 2,272 adults with COVID-19 requiring mechanical ventilation drawn from the Study of the Treatment and Outcomes in Critically Ill Patients with COVID-19 (STOP-COVID) multicenter cohort, we test the following three approaches to CSC algorithms: Sequential Organ Failure Assessment (SOFA) scores grouped into ranges, SOFA score ranges plus comorbidities, and a hypothetical approach using raw SOFA scores not grouped into ranges. We find that area under receiver operating characteristic (AUROC) curves for all three algorithms demonstrate only modest discrimination for 28-day mortality. Adding comorbidity scoring modestly improves algorithm performance over SOFA scores alone. The algorithm incorporating comorbidities has modestly worse predictive performance for Black compared to white patients. CSC algorithms should be empirically examined to refine approaches to the allocation of scarce resources during pandemics and to avoid potential exacerbation of racial inequities.<br />Competing Interests: The authors have no conflicts of interest relevant to this work. For unrelated work, the authors have the following disclosures: S.P.K. served as a consultant for Resolve to Save Lives and has previously led a partnership on multiple chronic conditions at the Icahn School of Medicine at Mount Sinai with Teva Pharmaceuticals. W.B.F. serves as a consultant for Alosa Health and Aetion. He also received an honorarium for a presentation to Blue Cross Blue Shield of Massachusetts. E.Y.K. is a co-investigator in NCT04389671 (Windtree Therapeutics) testing lucinactant (surfactant-like treatment) in COVID-19 patients and received unrelated research funding from Bayer AG, N.I.H., the American Heart Association, the American Lung Association, and the American Thoracic Society.<br /> (© 2021 The Author(s).)

Details

Language :
English
ISSN :
2666-3791
Volume :
2
Issue :
9
Database :
MEDLINE
Journal :
Cell reports. Medicine
Publication Type :
Academic Journal
Accession number :
34337554
Full Text :
https://doi.org/10.1016/j.xcrm.2021.100376